NEW YORK (GenomeWeb) – Veracyte said today that it has signed an agreement with Quest Diagnostics that will broaden access to the Afirma Gene Expression Classifier (GEC), a laboratory-developed test used to resolve indeterminate results on fine-needle-aspiration biopsies that were initially evaluated by cytopathology for potential thyroid cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.